Literature DB >> 23467315

Immune reactivity of Brucella melitensis-vaccinated rabbit serum with recombinant Omp31 and DnaK proteins.

Amir Ghasemi1, Mohammad Hossein Salari, Amir Hassan Zarnani, Mohammad Reza Pourmand, Hojat Ahmadi, Abbas Mirshafiey, Mahmood Jeddi-Tehrani.   

Abstract

BACKGROUND AND OBJECTIVES: Brucella melitensis infection is still a major health problem for human and cattle in developing countries and the Middle East.
MATERIALS AND METHODS: In this study, in order to screen immunogenic candidate antigens for the development of a Brucella subunit vaccine, a cytoplasmic protein (DnaK) and an outer membrane protein (Omp31) of B. melitensis were cloned, expressed in E.coli BL21 and then purified using Ni-NTA agarose. Immunized serum was prepared from a rabbit inoculated with attenuated B. melitensis. RESULTS AND
CONCLUSION: It was proved that immunized serum contains antibodies against recombinant Omp31 (rOmp31) and DnaK (rDnaK) by Western blot and ELISA assays. The results may suggest the importance of these proteins as subunit vaccines against B. melitensis as well as targets for immunotherapy.

Entities:  

Keywords:  Brucella; Cloning; ELISA; Immune Reactivity; Protein Expression; Purification

Year:  2013        PMID: 23467315      PMCID: PMC3577567     

Source DB:  PubMed          Journal:  Iran J Microbiol        ISSN: 2008-3289


INTRODUCTION

Brucella spp. are intracellular pathogens which were originally defined as facultative intracellular bacteria that preferentially infect macrophages (1, 2). Human infections with B. melitensis are endemic in many developing countries (3), and the incidence of brucellosis in livestock is of great economic concern due to reduced productivity, increased numbers of abortions and weak offspring, and is a major impediment to trade and export of livestock. Human brucellosis is a severe debilitating disease that requires prolonged treatment with several antibiotics, and also involves considerable medical expense, as well as loss of working hours (4). B. melitensis Rev.1, an attenuated smooth strain used to control B. melitensis infection gives heterologous protection against other Brucella spp. and is currently considered as the best vaccine for the prophylaxis of caprine brucellosis (5). However, major problems like the ability of this strain to cause infection in humans (6) and the development of resistance to streptomycin used to treat brucellosis, have made the health officials to prohibit its use for human vaccination (7). Therefore, a subunit vaccine that is protective against B. melitensis is desirable. There is an increasing interest in the study of immunogenicity and protective effects of Brucella outer membrane proteins (OMPs) and cytoplasmic proteins (8–10). For the first time Omp31 was cloned from Brucella melitensis 16M, and its predicted amino acid sequence was shown to have a significant homology (34% identity) with Brucella Omp25 (11). Omp31 is expressed in all Brucella species except in Brucella abortus (12). The molecular chaperone DnaK (Accession No. 1197260) belongs to the highly conserved hsp70 family, reflecting its important role in cellular metabolism (13). Induction of DnaK causes resistance to antimicrobial defense mechanisms of the macrophage in the host (14). In view of the immunological importance of the molecular chaperone DnaK and Omp31, we used purified recombinant Omp31 (rOmp31) and DnaK (rDnaK) from B. melitensis to assess the antibody response to these proteins in sera from a rabbit immunized with attenuated B. melitensis by ELISA and Western blot techniques.

MATERIALS AND METHODS

Bacterial strains and Immunization

B. melitensis 16M was obtained from the Brucella culture collection (Razi Institute,Tehran, Iran) and cultured as described (15). DNA was extracted using a DNA extraction kit (Bioneer, Daejeon, Korea). Escherichia coli strain TOP10 (Invitrogen, NY, USA) was used as host for cloning experiments and for propagation of plasmids. E. coli strain BL21 (DE3) (Stratagene, CA, USA) was used for expression of the recombinant proteins. A New Zealand White Rabbit was immunized intramuscularly with four doses of vaccine (108 CFU of attenuated B. melitensis Rev.1 in each dose) given 2 weeks apart. Sera were obtained before immunization and 2 weeks after the fourth dose of vaccine.

Cloning, expression and purification of rOmp31 and rDnaK

The Gateway cloning system (Invitrogen, NY, USA) was used for cloning of a 687 bp B. melitensis DNA fragment encoding Omp31 devoid of the putative signal peptide as previously described (16, 17). The forward primers contained the cacc sequence at the 5’ end followed by the bases of the gene sequences. The primers were as follows: Sense 5'CACCATGGCCGACGTGGTTGT 3’ and f antisense 5’ GAACTTGTAGTTCAGACC 3’. The open reading frame of DnaK consisting of 1317bp was cloned in the pET28a+ vector (Novagen, Madison, WI, USA) according to the manufacturer's instructions. The sequence information available in the B. melitensis genome was used to design specific primers for DnaK with NdeI and BamHI restriction sites at the 5’ ends. The primers were as follows: sense 5’ CATATGACACCTT CTG 3 ‘, antisense 5’ GGATCCTACCGACCAGCG 3’. B. melitensis genomic DNA was used as template for PCR amplification of the candidate genes using High Fidelity PCR Enzyme Mix (Fermentas, Vilnius, Lithuania). The amplified dnak gene from B. melitensis 16M was directly cloned into pTZ57R (InsTAclone™ PCR Cloning Kit) (Fermentas, Vilnius, Lithuania). Then the insert was subcloned to pET28a (+) and then transformed into E. coli strain TOP10 competent cells and miniprep plasmid DNA was purified from overnight cultures. The plasmid DNA of the clone containing the insert was used to transform E. coli strain BL21 (DE3) competent cells. Upon induction with 1 mM isopropyl-β-d-thiogalactopyranoside (IPTG) both recombinant proteins were successfully expressed in the insoluble fraction of E. coli cells. Purification of rDnaK and rOmp31 were done as described previously (16). Purity was assessed by SDS-PAGE and Coomassie blue staining. Endotoxin was removed from recombinant proteins by a phase separation with Triton X-114 (18, 19). These preparations had an endotoxin content of less than 0.05 endotoxin units per mg of protein assessed by Limulus amebocyte lysate analysis kit (Lonza, Basel, Switzerland). The concentration of each recombinant protein was determined by Bradford method (20).

Assessment of recombinant proteins using immunized rabbit serum: Western blot

To study the recognition of recombinant proteins by immunized rabbit serum, Western blot was used. Purified recombinant proteins were electrophoresed on a 12.5% polyacrylamide gel and transferred to a nitrocellulose membrane as mentioned above. The membrane was then incubated with immunized serum (1/2000) followed by horseradish peroxidase (HRP)-conjugated goat anti-rabbit immunoglobulin G (Avecina Research Institute, Tehran, Iran) with three washes between each step. The bound conjugates were then detected using diaminobenzidine (DAB).

ELISA

ELISA 96-well plates (Greinerbio-one, Frickenhausen, Germany) were coated with 100 µL of 1 µg/ml and 2.5 µg/ml of rOmp31, rDnaK respectively, resuspended in 0.1 M phosphate-buffered saline (PBS) and then incubated overnight at RT. Additional wells were coated with 100 µL B. melitensis lysate at 1 µg/mL in PBS as positive controls. The plates were then washed five times with PBS plus 0.05% Tween 20 (PBST) for 3 min each time. Three hundred µL of 10% fetal bovine serum (FBS) in PBS were plated and incubated for 2 h at room temperature. ELISA was then performed using 1:1000 dilutions of either normal rabbit serum or immunized rabbit serum. The plates were again washed with PBST as described earlier. One hundred µL of HRP-conjugated goat anti-rabbit immunoglobulin G (Avecina Research Institute, Tehran, Iran) (diluted 1/1000) were added to each well of the plate. The plates were again incubated for 1 h at room temperature. The plates were then washed with PBST and TMB (Pishtaz Teb, Tehran, Iran) was added to produce a color change. The reaction was stopped after 10 min by the addition of 30 µL of 20% H2SO4. An ELISA plate reader (Bio-Tek Instruments, Winooski, Vt.) was used to read the absorbance at 450-570 nm. All samples were tested in duplicates, with average absorbance values being reported.

RESULTS

Production of recombinant proteins

Transfection pDEST-omp31 and pET28-dnak into E.coli BL21 (DE3) competent bacteria resulted in production of the respective proteins with the expected sizes i.e. 48 kd for DNAK and 26kd for Omp31 proteins as revealed by SDS-PAGE (Fig. 1).
Fig. 1

SDS - PAGE analysis of purified rOmp31 and rDNAK Proteins with Coomassie blue staining 1; Purified Recombinant DnaK Protein, 2; Purified Recombinant Omp31 Protein, M; Protein Marker (Fermentas SM 671).

SDS - PAGE analysis of purified rOmp31 and rDNAK Proteins with Coomassie blue staining 1; Purified Recombinant DnaK Protein, 2; Purified Recombinant Omp31 Protein, M; Protein Marker (Fermentas SM 671).

Screening of recombinant proteins with immunized rabbit serum

Immunized rabbit serum, but not pre immunized serum, strongly reacted with B. melitensis lysate and at a lower extent with rOmp31 and rDNAK (Fig. 2A). The two B. melitensis recombinant proteins reacted strongly with the immunized rabbit serum in Western blot (Fig. 2B).
Fig. 2

Analysis of B. mellitensis recombinant proteins and lysate reactivity with immunized rabbit serum.

A. ELISA analysis of expressed recombinant Omp31, DnaK Protein and Lysate of B. mellitensis using rabbit immunized serum.

B. Western blot analysis of immune reactivity of immunized rabbit serum with rOmp31 (Lane 1), rDnak (lane 2) and M; Protein Marker (Fermentas SM 671).

Analysis of B. mellitensis recombinant proteins and lysate reactivity with immunized rabbit serum. A. ELISA analysis of expressed recombinant Omp31, DnaK Protein and Lysate of B. mellitensis using rabbit immunized serum. B. Western blot analysis of immune reactivity of immunized rabbit serum with rOmp31 (Lane 1), rDnak (lane 2) and M; Protein Marker (Fermentas SM 671).

DISCUSSION

New strategies are needed to protect brucellosis while avoiding the disadvantages of the currently used live vaccines. Subunit vaccines are an attractive approach for development of effective recombinant vaccines. Although considerable work has been carried out on numerous cell surface and intracellular components, only a few antigens have shown significant protective activity (2, 15, 21, 22). The molecular chaperone (Accession No. 1197260) is named as the gene coding for DnaK protein in GenBank but it is different from the previously described Brucella gene that expresses the DnaK protein (23, 24). No data about the immunological properties of this antigen has been reported yet, so we decided to study the potential of DnaK protein interaction with Brucella-immunized rabbit serum. rDnak was cloned, expressed and purified. It showed a clear reaction with immunized rabbit serum which correlates with the hypothesis that synthesis of Hsps may occur during a stress response of the infectious organism, triggered by the hostile environment encountered during host colonization (25). It thus may be rational to propose that for a subunit vaccine against B. melitensis or even as a target for immunotherapy. rOmp31, an outer membrane protein from B. melitensis was also cloned, expressed and purified in this study. This antigen has been shown to react with some but not all serum samples from human, dog, sheep and ram that had been infected with Brucella spp. (10). Moreover, rOmp31 has also been elegantly shown to react with human positive pooled serum (26). In addition, immunization of animals with B. ovis encoded rOmp31, alone or together with R-LPS type B.ovis, was reported to have developed an acceptable protection against B.ovis infection in the immunized mice (16). Analysis of rOmp31 interaction with immunized rabbit serum in the present study showed that rOmp31 could react much more strongly in ELISA than pre-immunized rabbit serum. These data may also suggest rOmp31 as a good candidate for subunit vaccine against B. melitensis.
  25 in total

Review 1.  Endotoxin removal from protein solutions.

Authors:  D Petsch; F B Anspach
Journal:  J Biotechnol       Date:  2000-01-21       Impact factor: 3.307

2.  Comparison of subcutaneous and conjunctival routes of Rev 1 vaccination for the prophylaxis of Brucella ovis infection in rams.

Authors:  C M Marín; M Barberán; M P Jiménez de Bagués; J M Blasco
Journal:  Res Vet Sci       Date:  1990-03       Impact factor: 2.534

3.  Heat-shock proteins and immunopathology: regulatory role of heat-shock protein-specific T cells.

Authors:  K Nomoto; Y Yoshikai
Journal:  Springer Semin Immunopathol       Date:  1991

4.  Removal of endotoxin from protein solutions by phase separation using Triton X-114.

Authors:  Y Aida; M J Pabst
Journal:  J Immunol Methods       Date:  1990-09-14       Impact factor: 2.303

5.  Quantitation of protein.

Authors:  C M Stoscheck
Journal:  Methods Enzymol       Date:  1990       Impact factor: 1.600

6.  Major heat shock gene of Drosophila and the Escherichia coli heat-inducible dnaK gene are homologous.

Authors:  J C Bardwell; E A Craig
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

7.  Antibody reactivity to Omp31 from Brucella melitensis in human and animal infections by smooth and rough Brucellae.

Authors:  Juliana Cassataro; Karina Pasquevich; Laura Bruno; Jorge C Wallach; Carlos A Fossati; Pablo C Baldi
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

8.  Cloning and expression of the immunoreactive Brucella melitensis 28 kDa outer-membrane protein (Omp28) encoding gene and evaluation of the potential of Omp28 for clinical diagnosis of brucellosis.

Authors:  Duraipandian Thavaselvam; Ashu Kumar; Sapana Tiwari; Manvi Mishra; Archana Prakash
Journal:  J Med Microbiol       Date:  2010-01-14       Impact factor: 2.472

Review 9.  Molecular host-pathogen interaction in brucellosis: current understanding and future approaches to vaccine development for mice and humans.

Authors:  Jinkyung Ko; Gary A Splitter
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

10.  The recombinant Omp31 from Brucella melitensis alone or associated with rough lipopolysaccharide induces protection against Brucella ovis infection in BALB/c mice.

Authors:  Silvia M Estein; Juliana Cassataro; Nieves Vizcaíno; Michel S Zygmunt; Axel Cloeckaert; Raúl A Bowden
Journal:  Microbes Infect       Date:  2003-02       Impact factor: 2.700

View more
  6 in total

1.  Design of a multi-epitope vaccine candidate against Brucella melitensis.

Authors:  Min Li; Yuejie Zhu; Ce Niu; Xinru Xie; Gulishati Haimiti; Wenhong Guo; Mingkai Yu; Zhiqiang Chen; Jianbing Ding; Fengbo Zhang
Journal:  Sci Rep       Date:  2022-06-16       Impact factor: 4.996

2.  OMP31 of Brucella melitensis 16M impairs the apoptosis of macrophages triggered by TNF-α.

Authors:  Ke Zhang; Hui Wang; Fei Guo; Li Yuan; Wanjiang Zhang; Yuanzhi Wang; Chuangfu Chen
Journal:  Exp Ther Med       Date:  2016-09-02       Impact factor: 2.447

3.  Immune reactivity of sera obtained from brucellosis patients and vaccinated-rabbits to a fusion protein from Brucella melitensis.

Authors:  Jafar Amani; Amir Ghasemi; Reza Ranjbar; Mahdi Shabani; Mahdi Zandemami; Reza Golmohammadi
Journal:  Iran J Basic Med Sci       Date:  2015-04       Impact factor: 2.699

4.  In silico analysis of chimeric TF, Omp31 and BP26 fragments of Brucella melitensis for development of a multi subunit vaccine candidate.

Authors:  Amir Ghasemi; Reza Ranjbar; Jafar Amani
Journal:  Iran J Basic Med Sci       Date:  2014-03       Impact factor: 2.699

5.  Immunoproteomic identification of immunodominant antigens independent of the time of infection in Brucella abortus 2308-challenged cattle.

Authors:  Jin Ju Lee; Hannah Leah Simborio; Alisha Wehdnesday Bernardo Reyes; Dae Geun Kim; Huynh Tan Hop; Wongi Min; Moon Her; Suk Chan Jung; Han Sang Yoo; Suk Kim
Journal:  Vet Res       Date:  2015-03-01       Impact factor: 3.683

6.  Fha Deficient Bordetella pertussis Isolates in Iran with 50 Years Whole Cell Pertussis Vaccination.

Authors:  Samaneh Saedi; Azadeh Safarchi; Faranak Tayebzadeh Moghadam; Siamak Heidarzadeh; Vajihe Sadat Nikbin; Fereshteh Shahcheraghi
Journal:  Iran J Public Health       Date:  2021-07       Impact factor: 1.429

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.